eligibility_summary
Include: consent, age 1 mo–75 y, prior allo-HSCT/solid organ Tx, primary immunodeficiency, or immunosuppression, neg pregnancy test/contraception, steroids taperable to <1 mg/kg/d before infusion, AdV/CMV/EBV infection persistent after ≥14 d therapy, refractory viremia, or intolerance, EBV PTLD/lymphoma (biopsy+ or high load if biopsy unsafe) or failure after 3 w anti-CD20. Exclude: ATG/alemtuzumab ≤28 d with CD3<10/µL, acute GVHD II–IV, DLI ≤14 d (except cord fraction), uncontrolled malignancy (except EBV+ PTLD/lymphoma), investigational ≤2 wks affecting VST, lactation, other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: Donor-derived, partially HLA-matched viral-specific T lymphocytes (biological, adoptive cell therapy) produced via Miltenyi CliniMACS cytokine capture technology. Donor PBMCs are stimulated with adenovirus/CMV/EBV antigens, IFN-γ–secreting T cells are immunomagnetically captured and infused (≈≤1×10^5 CD3+ cells/kg, repeat dosing possible). Mechanism of action: Enriched IFN-γ–producing CD8+/CD4+ T cells recognize HLA-presented viral peptides, secrete Th1 cytokines, and kill infected cells via perforin/granzyme, restoring antiviral immunity. Targets: Adenovirus-, CMV-, and EBV-infected cells (including EBV+ B cells in PTLD), pathways include TCR/HLA-restricted recognition, IFN-γ signaling, and cytotoxic effector mechanisms.